http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
만성 기관지 천식 환자에서 아젤라스틴의 치료효과에 관한 연구
조상헌,김우경,윤호주,민경업,김유영 대한천식알레르기학회 1994 천식 및 알레르기 Vol.14 No.1
Azelastine is an orally effective and long acting antiallergic agent with bronchodilating effect which has recently been developed for the treatment of bronchial asthma. Its properties have been described as H receptor blocker, LTC4 and LTD inhibitor, serotonin inhibitor, and bradykinin inhibitor, etc. In recent studies, azelastine also has been demonsrated effective in treating the symptoms of allergic rhinitis while producing a low incidence of side effects. As mentioned above, azelastine can be a promising agent in the treatment of patients with chronic bronchial asthma but unfortunately there is few reports on the efficacies of azelastine in the treatment of patients with chronic asthma in Korea. This study is performed to evaluate the effect of azelastine on symptoms, pulmonary function and nonspecific bronchial hyperres- ponsiveness in the treatment of patients with chronic bronchial asthma. Thirty four patients with mild to moderate asthma, between 19 to 60 years old, were participated in this study and the patients with severe or steroid dependent asthma or with cardiovascular disease or hepatic disease or renal disease were excluded. At the beginning of study, we evaluated the baseline values of subjects, which were symptom scores including cough, dyspnea, and number of use of p agonist in a week and PFT such as FEV1, PEFR and PC20-methacholine. After those parameters have been estimated, patients were prescribed with 4 mg azelastine or placebo a day for 4 weeks and then, after a wash-out period for a week, received placebo or 4 mg azelastine a day for 4 weeks. We evaluated the parameters just after placebo period and azelastine period and the results were statistically analyzed by paired t-test. Results were as follows 1) There was a significant improvement in asthmatic symptoms and reduction in the use agonist after the administration of 4mg azelastine a day for 4 weeks. 2) There was no significant change in FEV1 but a significant increase in PEFR after the administration of 4mg azelastine a day for 4 weeks. 3) No significant change of nonspecific bronchial hyperresponsiveness and few side effects were observed after the administra- tion of 4mg azelastine a day for 4 weeks. These results suggest that azelastine has an effect on symptomatic treatment and improvement of PEFR in patients with chronic bronchial asthma.